About: Endogenous IL‐12 synthesis is not required to prevent hyperexpression of type 2 cytokine and antibody responses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Endogenous IL‐12 synthesis is not required to prevent hyperexpression of type 2 cytokine and antibody responses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Endogenous IL‐12 synthesis is not required to prevent hyperexpression of type 2 cytokine and antibody responses
Creator	Rempel, Julia Hayglass, Kent Lewkowich, Ian
source	Medline; PMC
abstract	Endogenous IL‐12 production is hypothesized to play an essential role preventing spontaneous expression of type 2 responses, acting as a natural inhibitor limiting development of immediate hypersensitivity. Here, IL‐12‐deficient p35(– / –) and p40(– / –) mice were used to examine the role of endogenous IL‐12 and p40 homodimer during in vivo development of exogenous antigen‐driven responses. In the absence of deliberate immunization, IL‐12‐deficient mice exhibited greatly reduced serum IgG2a but IgG1 / IgE levels no higher than controls. Immunization to elicit polarized ovalbumin‐specific type 1 or type 2 dominant responses, or using Trichinella spiralis extract in the absence of adjuvants, led to IFN‐γ production of approximately 10 % of C57BL / 6 controls yet the kinetics and intensity of primary and secondary type 2 cytokine (IL‐4, IL‐5, IL‐13) and antibody (IgG1, IgE) responses, as well as functional IL‐12 receptor expression, were consistently unaltered. Thus, while IL‐12 provides an important positive signal for Th1 development, antigen exposure in its absence does not lead to generalized enhancement of type 2 cytokine or antibody responses. The data argue that endogenous IL‐12 production is not required as a constitutive negative regulator limiting induction or expression of type 2 effector responses.
has issue date	2000-08-28(xsd:dateTime)
bibo:doi	10.1002/1521-4141(200002)30:2<347::aid-immu347>3.0.co;2-h
bibo:pmid	10671189
has license	no-cc
sha1sum (hex)	4e92a2b9e9b76ebd6976ee318fda7fc71ff4e4e9
schema:url	https://doi.org/10.1002/1521-4141%28200002%2930:2%3C347::aid-immu347%3E3.0.co%3B2-h
resource representing a document's title	Endogenous IL‐12 synthesis is not required to prevent hyperexpression of type 2 cytokine and antibody responses
has PubMed Central identifier	PMC7163480
has PubMed identifier	10671189
schema:publication	Eur J Immunol
resource representing a document's body	covid:4e92a2b9e9b76ebd6976ee318fda7fc71ff4e4e9#body_text
is schema:about of	named entity 'IgE' named entity 'play' named entity 'deliberate' named entity 'p35' named entity 'IgG2a' named entity 'IgG1' named entity 'intensity' named entity 'production' named entity 'PRIMARY' named entity 'PREVENTING' named entity 'DEFICIENT' named entity 'IL-12' named entity 'IL-13' named entity 'p40' named entity 'Th1' named entity 'responses' named entity 'IFN' named entity 'secondary' named entity 'constitutive' named entity 'expression' named entity 'IL-5' named entity 'endogenous' named entity 'serum' named entity 'IL-12' named entity 'IL-4' named entity 'Th1' named entity 'antigen' named entity 'ovalbumin' named entity 'IgE' named entity 'p40' named entity 'antibody' named entity 'muscle' named entity 'University of Manitoba' named entity 'IL-12' named entity 'CD8' named entity 'ANOVA' named entity 'immunization' named entity 'mice' named entity 'OVA' named entity 'type 1' named entity 'homodimer' named entity 'immunological' named entity 'Th1' named entity 'deficient mice' named entity 'T. spiralis' named entity 'type 2' named entity 'asthma' named entity 'p40' named entity 'IgE' named entity 'mice' named entity 'mice' named entity 'IL-10' named entity 'atopy' named entity 'IgE' named entity 'IgG1' named entity 'mice' named entity 'cutaneous' named entity 'type 2 cytokine' named entity 'cytokines' named entity 'endogenous' named entity 'IL-13' named entity 'hepatotropic' named entity 'neurotropic' named entity 'Th0' named entity 'type 2' named entity 'type 2' named entity 'IL-4' named entity 'supernatant' named entity 'IL-5' named entity 'IL-12' named entity 'IL-12' named entity 'IL-4' named entity 'IL-4' named entity 'heavy chain' named entity 'type 2' named entity 'endogenous' named entity 'IgE' named entity 'Th2' named entity 'CD3'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software